Validation Data Gallery
Tested Applications
| Positive WB detected in | human placenta tissue, IFN gamma treated HeLa cells |
| Positive IHC detected in | human cervical squamous cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | SKOV-3 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:2000 |
| Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Published Applications
| KD/KO | See 3 publications below |
| WB | See 58 publications below |
| IHC | See 16 publications below |
| IF | See 10 publications below |
Product Information
13268-1-AP targets IDO1 in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human, mouse, rat, canine |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen | IDO1 fusion protein Ag3953 相同性解析による交差性が予測される生物種 |
| Full Name | indoleamine 2,3-dioxygenase 1 |
| Calculated molecular weight | 403 aa, 45 kDa |
| Observed molecular weight | 42 kDa |
| GenBank accession number | BC027882 |
| Gene Symbol | IDO1 |
| Gene ID (NCBI) | 3620 |
| RRID | AB_2123444 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P14902 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
IDO1 is the target for therapy in a range of clinical settings, including cancer, chronic infections, autoimmune and allergic syndromes, and transplantation. Elevated IDO1 expression is a hallmark of major viral infections including HIV, HBV, HCV or influenza and also of major bacteria infections, such as Tb, CAP, listeriosis and sepsis. Pathogens are able to highjack the immunosuppressive effects of IDO1 and make use of them to facilitate their own life cycle. MW of IDO1 is 40-42kd (PMID: 14502282; 17055065).
Protocols
| Product Specific Protocols | |
|---|---|
| WB protocol for IDO1 antibody 13268-1-AP | Download protocol |
| IHC protocol for IDO1 antibody 13268-1-AP | Download protocol |
| IF protocol for IDO1 antibody 13268-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Theranostics Single-cell RNA sequencing highlights the immunosuppression of IDO1+ macrophages in the malignant transformation of oral leukoplakia | ||
Hepatology Indoleamine-2, 3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B.
| ||
Acta Biomater Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy. | ||
ACS Appl Mater Interfaces Mitigation Effects of Selenium Nanoparticles on Depression-Like Behavior Induced by Fluoride in Mice via the JAK2-STAT3 Pathway. | ||
J Immunother Cancer GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer. | ||
J Immunother Cancer Tryptophan potentiates CD8+ T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation. |